ANTX Stock Price, AN2 Therapeutics, Inc. Quote, Chart

Market Summary

USD2.26-0.01

Market Closed

-0.44%

ANTX Stock Price

View Fullscreen

ANTX RSI Chart

ANTX Valuation

Market Cap

67.7M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

50.78

Price/Free Cashflow

-1.14

ANTX Price/Sales (Trailing)

ANTX Profitability

Return on Equity

-59.7%

Return on Assets

-54.45%

Free Cashflow Yield

-87.55%

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

ANTX Earnings

Earnings (TTM)

-66.0M

Earnings Growth (Yr)

-8.44%

Earnings Growth (Qtr)

1.66%

Breaking Down ANTX Revenue

52 Week Range

2.32

(Low)(High)

Last 7 days

-8.1%

Last 30 days

-8.1%

Last 90 days

-37.6%

Trailing 12 Months

-72.6%

How does ANTX drawdown profile look like?

ANTX Financial Health

Current Ratio

8.28

ANTX Investor Care

Shares Dilution (1Y)

53.55%

Diluted EPS (TTM)

-2.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	94.0K	307.0K	748.0K	1.4M
2021	0	0	0	69.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AN2 Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	krause kevin michael	acquired	-	-	30,000	chief strategy officer
Mar 15, 2024	eckburg paul	acquired	-	-	30,000	chief medical officer
Mar 15, 2024	chanda sanjay	acquired	-	-	27,500	chief development officer
Mar 15, 2024	eizen joshua m	acquired	-	-	30,000	chief legal officer
Mar 15, 2024	day lucy	acquired	-	-	27,500	chief financial officer
Mar 15, 2024	easom eric	acquired	-	-	99,000	chief executive officer

Which funds bought or sold ANTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	JANUS HENDERSON GROUP PLC	reduced	-4.6	-22,341,700	3,980,930	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	unchanged	-	-95,704,300	18,041,700	0.23%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-31.62	-399,948	48,660	-%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-274,402	-	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	unchanged	-	-494,219	93,168	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	144	-497,950	314,970	-%
May 15, 2024	Curi RMB Capital, LLC	unchanged	-	-792,041	149,311	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-28.93	-672,517	85,449	-%
May 15, 2024	Avidity Partners Management LP	added	0.88	-19,621,100	3,737,500	0.12%
May 15, 2024	Laurion Capital Management LP	unchanged	-	-755,353	142,396	-%

Are Funds Buying or Selling ANTX?

Are funds buying ANTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANTX

No. of Funds

Unveiling AN2 Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	frazier life sciences public fund, l.p.	2.4%	707,879	SC 13G
Feb 14, 2024	ra capital management, l.p.	18.7%	5,551,295	SC 13G/A
Feb 14, 2024	citadel advisors llc	5.2%	6	SC 13G/A
Feb 14, 2024	pfizer inc	4.58%	1,362,499	SC 13G/A
Feb 13, 2024	easom eric	5.2%	1,572,170	SC 13G
Feb 12, 2024	janus henderson group plc	4.3%	1,279,975	SC 13G/A
Feb 09, 2024	adjuvant global health technology fund, l.p.	7.0%	2,080,051	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	9.0%	2,678,209	SC 13G/A
Jul 25, 2023	tcg crossover gp i, llc	6.6%	1,289,320	SC 13G
Jul 05, 2023	janus henderson group plc	5.1%	1,000,076	SC 13G

Recent SEC filings of AN2 Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-K/A	Annual Report
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 10, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	PRE 14A	PRE 14A
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 29, 2024	10-K	Annual Report

Peers (Alternatives to AN2 Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

AN2 Therapeutics, Inc. News

Latest updates

AN2 Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	35.2%	630	466	228	27.00	27.00	25.00	15.00	2.00
Operating Expenses	6.0%	12,476	11,770	10,333	7,683	7,594	6,932	4,998	2,050
S&GA Expenses	11.4%	3,724	3,342	3,635	2,050	1,782	1,587	898	401
R&D Expenses	17.8%	8,752	7,428	6,698	5,633	5,312	5,345	3,850	1,649
Net Income	-4.4%	-11,842	-11,339	-10,120	-7,655	-7,545	-6,943	-5,007	-2,048
Net Income Margin	38.1%	-30.32*	-49.01*	-105.09*	-288.83*	-312.22*	-	-	-
Free Cashflow	19.5%	-7,638	-9,487	-9,595	-6,742	-8,993	-4,691	-5,257	-1,543

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-12.6%	121	139	154	99.00	91.00	103	110	120	121	65.00
Current Assets	5.3%	116	111	126	98.00	90.00	99.00	107	117	120	60.00
Cash Equivalents	58.3%	25.00	16.00	33.00	41.00	27.00	27.00	29.00	41.00	83.00	12.00
Liabilities	-24.1%	11.00	14.00	15.00	11.00	9.00	7.00	4.00	4.00	5.00	3.00
Current Liabilities	-100.0%	-	14.00	15.00	11.00	9.00	7.00	4.00	4.00	5.00	3.00
Shareholder's Equity	-11.3%	111	125	139	88.00	83.00	95.00	106	116	115	-47.41
Retained Earnings	-10.8%	-171	-154	-137	-120	-105	-89.72	-77.88	-66.54	-56.42	-47.38
Additional Paid-In Capital	1.0%	282	279	277	209	188	185	184	183	172	-
Shares Outstanding	0.1%	30.00	30.00	30.00	22.00	19.00	19.00	14.00	11.00	3.00	3.00
Float	-	-	-	-	109	-	-	-	119	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Cashflow From Operations	-3.1%	-17,593	-17,068	-11,800	-12,824	-11,596	-7,638	-9,487	-9,595	-6,742	-8,993	-4,691	-5,257	-1,543
Share Based Compensation	6.9%	2,385	2,232	2,169	1,943	2,068	1,472	1,228	1,242	449	433	354	179	8.00
Cashflow From Investing	6159.5%	26,290	420	-62,462	7,877	10,887	6,055	-2,317	-39,486	13,977	-	-	-	-
Cashflow From Financing	208.7%	349	-321	66,066	19,050	199	-	-10.00	7,178	63,187	-969	-240	-	79,744

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANTX Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 14,655	$ 11,985
General and administrative	3,641	4,054
Total operating expenses	18,296	16,039
Loss from operations	(18,296)	(16,039)
Other income, net	1,679	716
Net loss attributable to common stockholders	$ (16,617)	$ (15,323)
Net loss per share attributable to common stockholders, basic	$ (0.56)	$ (0.79)
Net loss per share attributable to common stockholders, diluted	$ (0.56)	$ (0.79)
Weighted-average number of shares used in computing net loss per share, basic	29,763,278	19,385,646
Weighted-average number of shares used in computing net loss per share, diluted	29,763,278	19,385,646
Other comprehensive loss:
Unrealized (loss) gain on investments	$ (222)	$ 199
Comprehensive loss	$ (16,839)	$ (15,124)

ANTX Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 24,693	$ 15,647
Short-term investments	89,517	91,648
Prepaid expenses and other current assets	2,103	3,212
Total current assets	116,313	110,507
Long-term investments	3,904	27,194
Other assets, long-term	1,043	1,043
Total assets	121,260	138,744
Current liabilities:
Accounts payable	2,433	2,676
Accrued compensation	995	4,018
Accrued liabilities	6,914	6,681
Other current liabilities	321	668
Total liabilities	10,663	14,043
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 29,815,663 and 29,741,445 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	281,616	278,881
Accumulated other comprehensive gain	53	275
Accumulated deficit	(171,072)	(154,455)
Total stockholders' equity	110,597	124,701
Total liabilities and stockholders' equity	$ 121,260	$ 138,744

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

CEO	Mr. Eric E. Easom
WEBSITE	an2therapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	35

AN2 Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for AN2 Therapeutics, Inc.? What does ANTX stand for in stocks?

ANTX is the stock ticker symbol of AN2 Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AN2 Therapeutics, Inc. (ANTX)?

As of Thu May 16 2024, market cap of AN2 Therapeutics, Inc. is 67.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers.

What is the fair value of ANTX stock?

You can check ANTX's fair value in chart for subscribers. The fair value of AN2 Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AN2 Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AN2 Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANTX is over valued or under valued. Whether AN2 Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact AN2 Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANTX.

What is AN2 Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ANTX's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 50.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANTX PE ratio will change depending on the future growth rate expectations of investors.